Skip to main content
    M

    Maravai Lifesciences Holdings Inc (MRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.40
    -0.14 (-1.86%)

    Market Cap: $1.96B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Maravai Lifesciences Holdings Inc (MRVI) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Maravai Lifesciences Holdings (MRVI) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Maravai Lifesciences Holdings reported EPS of -$0.08, below the -$0.07 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    43%(10/23)
    Avg Surprise
    -32.91%

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.04
    Range-$0.06 - -$0.02
    11 analysts
    Revenue Consensus
    $52.20M
    Range$48.41M - $54.70M
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.01
    Range-$0.04 - $0.01
    4 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00-86.1%
    60d ago$0.00-86.1%
    30d ago$0.00-86.1%
    7d ago$0.00-86.1%
    Current-$0.01
    Revenue Consensus
    $61.09M
    Range$54.20M - $70.00M
    7 analysts

    Next Report

    MRVI has an expected report date of Feb 23, 2027.

    MRVI Earnings Call

    The latest MRVI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, MRVI beat 10, missed 11 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $45.85M, up 10.1% from $41.63M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.08-$0.07-$0.08 - -$0.04-14.29%MissN/A92 up, 4 downNov 4, 2026$45.85M
    Jun 30, 2026-$0.07-$0.07N/A0.00%In lineN/A60 up, 1 downAug 6, 2026$51.44M
    Mar 31, 2026$0.01-$0.05-$0.07 - -$0.03+120.00%BeatN/A83 up, 2 downMay 7, 2026$65.84M
    Dec 31, 2025-$0.04-$0.07-$0.10 - -$0.06+43.02%BeatN/A103 up, 3 downFeb 25, 2026$49.87M
    Sep 30, 2025-$0.08-$0.08-$0.12 - -$0.030.00%In lineN/A114 up, 6 downNov 6, 2025$41.63M
    Jun 30, 2025-$0.08-$0.07-$0.12 - -$0.03-14.29%MissN/A123 up, 10 downAug 11, 2025$47.40M
    Mar 31, 2025-$0.08-$0.07-$0.11 - -$0.04-14.29%MissN/A140 up, 12 downMay 12, 2025$46.85M
    Dec 31, 2024-$0.06-$0.04-$0.06 - -$0.02-49.63%Miss-700.0%152 up, 0 downMar 18, 2025$56.56M
    Sep 30, 2024-$0.02-$0.01-$0.02 - $0.02-100.00%MissN/A130 up, 0 downNov 7, 2024$69.03M
    Jun 30, 2024-$0.06$0.00-$0.01 - $0.02N/AN/AN/A120 up, 0 downAug 7, 2024$69.42M
    Mar 31, 2024-$0.02-$0.03-$0.03 - -$0.02+33.33%Beat-166.7%111 up, 0 downMay 8, 2024$64.18M
    Dec 31, 2023$0.01-$0.01-$0.02 - $0.00+200.00%Beat-97.1%111 up, 0 downFeb 22, 2024$74.14M
    Sep 30, 2023-$0.01$0.01-$0.01 - $0.02-200.00%Miss-102.7%110 up, 0 downNov 7, 2023$66.86M
    Jun 30, 2023-$0.05$0.01$0.00 - $0.04-600.00%Miss-109.3%120 up, 0 downAug 7, 2023$68.91M
    Mar 31, 2023$0.03$0.04$0.02 - $0.06-25.00%Miss-94.4%120 up, 0 downMay 8, 2023$79.03M
    Dec 31, 2022$0.35$0.34$0.32 - $0.38+2.94%Beat-22.2%121 up, 0 downFeb 22, 2023$204.71M
    Sep 30, 2022$0.37$0.33$0.29 - $0.38+12.12%Beat+311.1%100 up, 0 downNov 2, 2022$191.26M
    Jun 30, 2022$0.54$0.45$0.39 - $0.48+20.00%Beat+22.7%91 up, 1 downAug 4, 2022$242.73M
    Mar 31, 2022$0.54$0.44$0.41 - $0.46+22.73%Beat+2600.0%91 up, 0 downMay 5, 2022$244.29M
    Dec 31, 2021$0.45$0.38$0.35 - $0.43+18.42%Beat+246.2%90 up, 0 downFeb 23, 2022$228.44M
    Sep 30, 2021$0.09$0.17N/A-47.06%MissN/A9N/ANov 10, 2021$204.81M
    Jun 30, 2021$0.44$0.02N/AN/AN/AN/A10N/AAug 10, 2021$217.78M
    Mar 31, 2021$0.02$0.07N/A-71.43%MissN/A10N/AMay 10, 2021$148.21M
    Dec 31, 2020$0.13$0.11$0.05 - $0.17+18.18%BeatN/A10N/AMar 2, 2021$98.35M
    Sep 30, 2020-$0.02$0.17N/A-111.76%MissN/AN/AN/ANov 23, 2020$87.86M
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.28, after -$0.16 the year before. It was $0.11 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.28N/A
    Dec 31, 2024-$0.16N/A
    Dec 31, 2023-$0.02-101.1%
    Dec 31, 2022$1.80+80.0%
    Dec 31, 2021$1.00+809.1%
    Dec 31, 2020$0.11N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,27912
    2026Q2Jun 30, 20265,11811
    2026Q1Mar 31, 20264,98111
    2025Q4Dec 31, 20256,31913
    2025Q3Sep 30, 20255,45711
    2025Q2Jun 30, 20258,00815
    2025Q1Mar 31, 20258,12312
    2024Q4Dec 31, 20248,63414

    2026Q3 Earnings Call

    Opening remarks

    Debra Hart Executive Good afternoon, everyone. Thanks for joining us for our third quarter 2026 earnings call. The press release and the slides that accompany today's call are available at investors.maravai.com. As you can see from the agenda on Slide 2, our CEO, Bernd Brust, will provide a business update, and our CFO, Rajesh J. Asorpota, will review our financial results. Dr. Chanfeng Zhao, our Chief Scientific Officer, and Kurt Oreshack, our executive vice president and general counsel, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. Actual results could differ materially from expectations, and we undertake no obligation to update them. We refer you to Slide 3 for details on our forward-looking statements, and Slide 4 for our use of non-GAAP financial measures. The press release and the slides provide reconciliations to the directly comparable GAAP measures, and we also post reconciling schedules to our investor website. Please also refer to the risk factors in Maravai's annual report on Form 10-K for 2025, our subsequent quarterly reports on Form 10-Q, and our other SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I will turn the call over to Bernd.

    Bernd Brust CEO Good afternoon, and thank you for joining us. We are pleased with our third quarter performance, which builds on the momentum we established in the first half of the year. Our results reflect solid execution across the business and reinforce our confidence in both our near-term outlook and long-term strategy. During the quarter, we generated revenue of $45.9 million, representing 10% year-over-year growth. TriLink revenue increased 12%, led by strong demand for our mRNA products. mRNA revenue was up 28% year over year. Within mRNA, GMP consumables grew 30%, and discovery was up 27%. We had no high-volume CleanCap revenue for commercial-phase COVID vaccine programs in the quarter. CDMO revenue grew 8%, while specialty chemistry was down 4% as some large orders from Q3 of 2025 did not repeat in the quarter this year. Cygnus also delivered a solid quarter, with revenue growing 8%. This is the sixth consecutive quarter of year-over-year growth for Cygnus. From a profitability standpoint, adjusted gross margin expanded more than 1,700 basis points year over year to 57.7%, while adjusted EBITDA improved by $16.6 million to $5.8 million. These results reflect higher revenue, a favorable product mix, and the benefits of the operating model we have built over the past year. Now let's turn to Slide 7 and highlight some of the landmark clinical progress we are seeing in our largest, most strategic part of the business, the mRNA market.

    Frequently Asked Questions About MRVI

    When is Maravai Lifesciences Holdings's next earnings date?

    Maravai Lifesciences Holdings's next earnings report is expected for Feb 23, 2027.

    Did MRVI beat earnings estimates last quarter?

    No. Maravai Lifesciences Holdings reported EPS of -$0.08 for the quarter ended Sep 30, 2026, below the -$0.07 estimate by 14.29%.

    What EPS do analysts expect from MRVI next quarter?

    The consensus EPS estimate for Maravai Lifesciences Holdings for the quarter ending Dec 31, 2026 is -$0.04 from 11 analysts, with estimates from -$0.06 to -$0.02.

    How often does MRVI beat earnings estimates?

    Maravai Lifesciences Holdings beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of +8.82%.